Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: The ASCENT (CCR102881) study

UCLA Center for Care, Los Angeles, CA, United States.
Antiviral therapy (Impact Factor: 3.02). 01/2008; 13(2):297-306.
Source: PubMed


This Phase IIb study explored the antiviral activity and safety of the investigational CCR5 antagonist aplaviroc (APL) in antiretroviral-naive patients harbouring R5-tropic virus.
One hundred and forty-seven patients were randomized 2:2:1 to one of two APL dosing regimens or efavirenz (EFV). All dosage arms were administered twice daily and in combination with lamivudine/zidovudine (3TC/ZDV; Combivir, COM). Efficacy, safety, and pharmacokinetic parameters were assessed.
This study was prematurely terminated due to APL-associated idiosyncratic hepatotoxicity. The primary endpoint of the study was the proportion of patients with plasma HIV-1 RNA <400 copies/ml who remained on randomized treatment through week 12. Of the 147 patients enrolled, 145 patients received one dose of treatment and were included in the intention-to-treat population. The proportion of patients with HIV-1 RNA <400 copies/ml at week 12 was 53%, 50% and 66% in the APL 600 mg twice daily, APL 800 mg twice daily, and EFV arms, respectively. Common clinical adverse events (AEs) were diarrhoea, nausea, fatigue and headache. APL demonstrated non-linear pharmacokinetics with high interpatient variability. In addition to the hepatic findings, there was an apparent dose-response relationship in the incidence of diarrhoea.
Whereas target plasma concentrations of APL were achieved, the antiviral activity of APL as the third agent in a triple drug regimen did not appear to be comparable to EFV in this treatment-naive patient population.

11 Reads
  • Source
    • "The identification of CCR5 as an HIV-1 coreceptor (Alkhatib et al., 1996; Choe et al., 1996; Deng et al., 1996; Dragic et al., 1996), prompted by the discovery of CCR5 ligand βchemokines with antiviral activity (Cocchi et al., 1995), led to the development of antiretroviral CCR5 inhibitors, including small molecules and antibodies. In clinical trials of HIV-1 patients infected with CCR5-tropic HIV-1 only (R5 strains), these agents have achieved potent viral suppression (Currier et al., 2008; Gulick et al., 2008; Gulick et al., 2007; Landovitz et al., 2008; Suleiman et al., 2010; Wilkin et al., 2010; Yeni et al., 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: R5 HIV-1 strains resistant to the CCR5 antagonist Maraviroc (MVC) can use drug-bound CCR5. We demonstrate that MVC-resistant HIV-1 exhibits delayed kinetics of coreceptor engagement and fusion during drug-bound versus free CCR5 infection of cell lines. Antibodies directed against the second extracellular loop (ECL2) of CCR5 had greater antiviral activity against MVC-bound compared to MVC-free CCR5 infection. However, in PBMCs, only ECL2 CCR5 antibodies HGS004 and HGS101, but not 2D7, inhibited infection by MVC resistant HIV-1 more potently with MVC-bound than with free CCR5. In addition, HGS004 and HGS101, but not 2D7, restored the antiviral activity of MVC against resistant virus in PBMCs. In flow cytometric studies, CCR5 binding by the HGS mAbs, but not by 2D7, was increased when PBMCs were treated with MVC, suggesting MVC increases exposure of the relevant epitope. Thus, HGS004 and HGS101 have antiviral mechanisms distinct from 2D7 and could help overcome MVC resistance.
    Virology 03/2011; 411(1):32-40. DOI:10.1016/j.virol.2010.12.029 · 3.32 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Maraviroc belongs to a new class of anti-HIV drugs named CCR5 antagonists, which block HIV entry into cells. It has proven potent efficacy in treatment-experienced patients with multiple drug failure. Its favourable toxicity profile makes the drug attractive for consideration in other clinical scenarios, including patients with earlier stages of disease, cardiovascular risk and viral hepatitis coinfection. Because of its unique mechanism of action-blocking viral entry, studies in patients with primary HIV infection and in the context of preexposure and postexposure prophylaxis are particularly warranted. However, given its exclusive activity against CCR5 tropic strains, viral tropism testing is mandatory before using CCR5 antagonists in the clinic. Efforts to improve the reliability of viral tropism assessment using genotypic tests are underway, and it is likely that these tools will soon replace phenotypic assays, which are more expensive, difficult to perform and take a long time.
    AIDS (London, England) 12/2008; 22(17):2231-40. DOI:10.1097/QAD.0b013e3283136d95 · 5.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The CCR102881 (ASCENT) study evaluated the antiviral activity of the novel CCR5 entry inhibitor aplaviroc plus a fixed-dose combination of lamivudine-zidovudine (Combivir) in drug-naïve human immunodeficiency virus type 1-infected subjects with only CCR5-tropic virus detected in plasma. Although the trial was stopped prematurely due to idiosyncratic hepatotoxicity, eight subjects met protocol-defined virologic failure criteria. Clonal analyses of the viral envelope tropism, aplaviroc susceptibility, and env sequencing were performed on plasma at baseline and at the time of virologic failure. Molecular evolutionary analyses were also performed. The majority of the subjects with virologic failure (six of eight) acquired the lamivudine resistance-associated mutation M184V, and none had evidence of reduced susceptibility to aplaviroc at the time of virologic failure, even at the clonal level. Six subjects with virologic failure maintained CCR5 tropism, while two exhibited a change in population tropism readout to dual/mixed-tropic with R5X4-tropic clones detected prior to therapy. Two evolutionary patterns were observed: five subjects had no evidence of population turnover, while three subjects had multiple lines of evidence for env population turnover. The acquisition of the M184V mutation is the primary characteristic of virologic failure in first-line therapy with aplaviroc plus lamivudine-zidovudine, regardless of the envelope tropism.
    Antimicrobial Agents and Chemotherapy 03/2009; 53(3):1116-23. DOI:10.1128/AAC.01055-08 · 4.48 Impact Factor
Show more


11 Reads
Available from